Rhythm Pharmaceuticals (RYTM) Projected to Post Quarterly Earnings on Wednesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.71) per share and revenue of $38.48 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Rhythm Pharmaceuticals Trading Down 2.5 %

Shares of Rhythm Pharmaceuticals stock opened at $54.66 on Tuesday. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of -12.62 and a beta of 2.14. The firm’s 50 day simple moving average is $57.11 and its two-hundred day simple moving average is $54.18.

Analyst Ratings Changes

A number of analysts have recently weighed in on RYTM shares. TD Cowen increased their price objective on shares of Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Oppenheimer started coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Wednesday, February 19th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $68.09.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 2,215 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $126,742.30. Following the transaction, the chief financial officer now directly owns 109,929 shares of the company’s stock, valued at $6,290,137.38. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Christopher Paul German sold 635 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the transaction, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,787 shares of company stock valued at $1,901,443. Corporate insiders own 5.60% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.